Table 1 Comparison of clinicopathological features between epidermal growth factor receptor mutant and mutation-wild patients with pathological stage IB-IIIA lung cancer
Total n = 535 | Mt (n = 208) | Wt (n = 358) | p valuesa) |
|---|---|---|---|
Age | 70 (35–90) | 70 (36–90) | 0.789b) |
Male, (%) | 86 (41.3) | 260 (72.6) | < 0.001 |
Smoking history +, (%) | 93 (44.7) | 287 (80.2) | < 0.001 |
Left side, (%) | 74 (35.6) | 142 (39.7) | 0.370 |
CEA (> 10 ng/ml) | 34 (16.3) | 61 (17.0) | 0.907 |
CT tumor size, (cm) | 3.1 (1.5–9.2) | 3.4 (0.8–11.6) | 0.033b) |
Consolidation size, (cm) | 2.7 (1.1–9.2) | 3.2 (0.6–11.0) | 0.001b) |
GGO absent, (%) | 128 (61.5) | 306 (85.5) | < 0.001 |
PET maxSUV | 4.9 (0.89–21.2) | 7.4 (0–33.7) | < 0.001b) |
Lobectomy | 199 (95.7) | 334 (93.3) | 0.270 |
Invasive lepidic adenocarcinoma, (%) | 24 (11.5) | 24 (6.7) | 0.060 |
Invasive acinar adenocarcinoma, (%) | 78 (37.5) | 76 (21.2) | < 0.001 |
Invasive papillary adenocarcinoma, (%) | 77 (37.0) | 85 (23.7) | 0.001 |
Invasive mucinous adenocarcinoma, (%) | 1 (0.5) | 44 (12.3) | < 0.001 |
Invasive solid adenocarcinoma, (%) | 14 (6.7) | 104 (29.1) | < 0.001 |
Invasive micropapillary adenocarcinoma, (%) | 11 (5.3) | 4 (1.1) | 0.004 |
High-grade adenocarcinoma | 28 (13.5) | 126 (45.2) | < 0.001 |
Lymphatic vessel invasion +, (%) | 78 (37.5) | 86 (24.0) | 0.002 |
Blood vessel invasion +, (%) | 122 (58.7) | 198 (56.3) | 0.482 |
Pleural invasion +, (%) | 125 (60.1) | 197 (55.3) | 0.253 |
Nodal metastasis +, (%) | 107 (51.4) | 125 (34.9) | < 0.001 |
 pN1 | 47 (22.6) | 66 (18.4) | 0.233 |
 pN2 | 60 (28.8) | 59 (16.5) | < 0.001 |
Lepidic component +, (%) | 185 (88.9) | 195 (54.5) | < 0.001 |
Solid component +, (%) | 109 (52.4) | 240 (67.0) | < 0.001 |
Micropapillary component +, (%) | 121 (58.2) | 128 (35.8) | < 0.001 |
Adjuvant chemotherapy, (%) | 84 (40.4) | 124 (34.6) | 0.176 |
Pathological stage | |||
 Stage IB | 82 (39.4) | 142 (39.7) |  |
 Stage II | 54 (26.0) | 128 (35.8) |  |
 Stage IIIA | 72 (34.6) | 88 (24.6) | 0.014 |
Recurrence +, (%) | 92 (44.2) | 121 (33.8) | 0.015 |
Initial site of recurrence, (%) | |||
 Central nerve system | 17 (8.2) | 16 (4.5) | 0.192 |
 Bone | 21 (10.1) | 23 (6.4) | 0.143 |
 Abdominal organ | 10 (4.8) | 24 (6.7) | 0.463 |
 Lung | 29 (13.9) | 41 (11.5) | 0.428 |
 Cervico-thoracic lymph-node | 38 (18.3) | 43 (12.0) | 0.047 |
 Pleural dissemination | 23 (11.1) | 15 (4.2) | 0.003 |
Distant or intrathoracic, (%) | |||
 Distant | 37 (17.8) | 57 (15.9) | 0.639 |
 Intrathoracic | 76 (36.5) | 84 (23.5) | 0.001 |
EGFR mutation, (%) | |||
 Exon 21 L858R | 96 (46.2) |  |  |
 Exon 19 deletion | 112 (53.8) |  |  |